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Abstract
Photoacoustic tomography is a recently developed imaging modality that can provide high
spatial-resolution images of hemoglobin distribution in tissues such as the breast. Because
breast cancer is an angiogenesis-dependent type of malignancy, we evaluated the clinical
acceptability of breast tissue images produced using our first prototype photoacoustic mam-
mography (PAM) system in patients with known cancer. Post-excisionally, histological sec-
tions of the tumors were stained immunohistochemically (IHC) for CD31 (an endothelial
marker) and carbonic anhydrase IX (CAIX) (a marker of hypoxia). Whole-slide scanning and
image analyses were used to evaluate the tumor microvessel distribution pattern and to cal-
culate the total vascular perimeter (TVP)/area for each lesion. In this clinical study, 42 lesions
were primarily scanned using PAM preoperatively, three of which were reported to be benign
and were excluded from statistical analysis. Images were produced for 29 out of 39 cancers
(visibility rate = 74.4%) at the median depth of 26.5 (3.25–51.2) mm. Age, menopausal status,
body mass index, history of neoadjuvant treatment, clinical stage and histological tumor
angiogenesis markers did not seem to affect the visibility. The oxygen saturation level in all of
the measured lesions was lower than in the subcutaneous counterpart vessels (Wilcoxon
test, p value<0.001), as well as in the counterpart contralateral normal breast region of inter-
est (ROI) (Wilcoxon test, p value = 0.001). Although the oxygen saturation level was not sta-
tistically significant between CAIX-positive vs. -negative cases, lesional TVP/area showed a
positive correlation with the oxygen saturation level only in the group that had received ther-
apy before PAM. In conclusion, the vascular and oxygenation data obtained by PAM have
great potential for identifying functional features of breast tumors.
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Introduction
In 2012, breast cancer represented one out of every four cancer diagnoses worldwide [1]. Breast
cancer is the second most common cancer in the world and the most frequent cancer among
women but has a favorable survival rate when diagnosed in the early stages. Indeed, greater
than 95% of breast cancer patients will survive for more than 5 years if diagnosed in the local
stage [2]. However, highly sensitive screening methods have yet to be established. Conventional
X-ray mammography (MMG), clinical breast exam (CBE) and self-breast exams, which are the
accepted screening methods for early detection, have limited advantages in some types of
breasts [3]. For instance, lesions in dense breasts are difficult to detect by MMG or even CBE
[4], although ultrasonography (US) is a useful approach for evaluating dense breasts, as well as
for confirming cysts. Other imaging modalities, such as magnetic resonance imaging (MRI),
can be applied as an additional diagnostic step when an abnormality is detected by MMG or
CBE. Although MRI can be a screening option for certain high-risk women, such as those with
a positive family history of breast cancer or a history of therapeutic chest irradiation at earlier
ages, it has not yet been proven to be beneficial for the general population [5].
In recent years, there has been a lot of progress in the development of optical imaging tech-
niques for breast cancer diagnosis [6]. These techniques have drawn attention because they do
not use ionizing radiation, like MMG, or need intravenous contrast agents, like MRI. Using
near-infrared (NIR) light, it is possible to develop an image of the distribution of hemoglobin
and oxygen saturation inside the breast tissue non-invasively, thus showing the potential for
measuring angiogenesis in the breast [7]. The development of neovasculature has been shown
to occur as early as when hyperplasia occurs in the mammary ducts [8]. Carpenter et al.
showed that periductal microvessel density (MVD) was more than twenty times higher when
compared to simple hyperplasia and normal ducts, which suggests that angiogenesis can be an
ideal factor in the evaluation of breast abnormalities. Furthermore, there are reports indicating
that MVD decreases significantly in patients who have responded to neoadjuvant chemothera-
pies [9, 10], thus making angiogenesis a potential imaging target to evaluate the grade of
response to therapies.
Photoacoustic mammography (PAM) is a new technique in which a near-infrared laser is
irradiated to the breast, and thermostatic waves produced by oxy (HbO2) and deoxy hemoglo-
bin (Hb) inside the breast tissue are detected by ultrasound detectors [11]. As a result of angio-
genesis, normal and abnormal breast tissues have different hemoglobin concentrations, and
this provides a natural optical absorption contrast that may be imaged using PAM technology.
Moreover, as ultrasound shows less scattering in the breast tissue, PAM shows higher spatial
resolution than other optical techniques, such as diffuse optical tomography (DOT), in which
light sources are used to obtain the hemoglobin distribution pattern in breast tissue [12].
We previously reported our initial clinical results of the first version of a prototype machine
for a dual illuminated mode photoacoustic tomography system (Canon Inc., Tokyo, Japan; S1
Fig) used in Kyoto University Hospital [13]. Here, we report the final data from the first clinical
trial that was conducted to study the usefulness of this machine in breast cancer patients in
relation to the histological assessment of angiogenesis and hypoxia.
Materials and Methods
Patients
Patients with primary breast lesions who met the following criteria and provided written con-
sent were enrolled in the study. The inclusion criteria were as follows: 20 years old or older at
the time of diagnosis, a breast mass scheduled for surgical excision and Eastern Cooperative
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Oncology Group performance status of 0 or 1. The exclusion criteria included the following:
scheduled for therapies other than surgery after PAM, pregnancy, suspicion of pregnancy,
ongoing photodynamic therapy with photosensitizing agents such as Photofrin1, breast
implants, cardiac pacemaker and any other conditions that made the patient unsuitable for
participation in the study according to each clinical investigator. A total of 57 patients were
considered for the study between August 2010 and March 2012 in Kyoto University Hospital,
Japan. The primary surgery was performed within 1 month after PAMmeasurement. No
patient received neoadjuvant therapy within this interval. All patients had undergone routine
radiological (MMG, US and/or MRI) and histological diagnosis (core biopsy) prior to surgery.
The study protocol was approved by the Medical Ethical Committee of Kyoto University
(UMIN000003406).
Pathologic diagnosis
After surgery, excised specimens were sectioned at 5 mm intervals perpendicular to the longest
axis of a specimen, and permanent pathologic analysis was performed on formalin-fixed paraf-
fin-embedded (FFPE) tissues by conventional hematoxylin-eosin (HE) staining. For invasive
breast carcinoma (IBC) and ductal carcinoma in situ (DCIS), estrogen receptor (ER) and pro-
gesterone receptor (PgR) status were confirmed by immunohistochemistry (IHC). Human epi-
dermal growth factor receptor 2 (HER2) status was confirmed by IHC or fluorescent in situ
hybridization. Ki-67 immunostaining was performed using the MIB1 monoclonal antibody
(Dako, Copenhagen, Denmark). for IBCs. The Ki-67 index was expressed as the percentage of
Ki-67-positive malignant cells in 1,000 malignant cells assessed under high-power magnifica-
tion (400×). A cut-off point of 14% was used to divide tumors into the low- vs. high-Ki67
group. Histological grade was calculated by a breast pathologist (13 years of experience)
according to the General Rules for Clinical and Pathological Recording of Breast Cancer, 15th
edition, based on nuclear pleomorphic, tubule formation, and mitotic count scores for IBCs.
The Histopathological Criteria for Assessment of Therapeutic Response of the Japanese Breast
Cancer Society was applied to examine the pathological effect of primary systemic therapy
(PST) for subjects who had received therapy before PAM.
Histological assessment of angiogenesis
Two consecutive 4 μm sections from tumors containing FFPE blocks were received and
mounted on glass slides for each case. Anti-CD31 monoclonal antibody JC70A (Dako) was
used for visualizing microvessels by IHC for each tumor containing sections at a dilution of
1:50 overnight after heat-induced antigen retrieval in Dako Target Retrieval solution pH 9 for
30 minutes, as instructed by the manufacturer. Sections were immunohistochemically stained
for carbonic anhydrase IX (CAIX), as a marker of hypoxia, with the monoclonal antibody M75
(BioScience, Bratislava, Slovakia) at a dilution of 1:150 for one hour at room temperature with-
out any antigen retrieval. Cytoplasmic membrane staining in cancerous epithelial cells was
considered positive (Fig 1A). Lesions were categorized into the positive vs. negative CAIX
groups based on focal staining in any of the analyzed sections from a given lesion. Whole histo-
logical glass slides were mounted with a coverslip and scanned with Virtual Slide Scanner,
NanoZoomer 2.0 (Hamamatsu Photonics, Hamamatsu, Japan) using a 20x objective lens. His-
tological regions of interest (ROIs) were highlighted on HE slides, and the area was measured
using the NanoZoomer Viewer (Hamamatsu Photonics).
For CD31 whole-slide image analysis, 105 jpeg files with 24-bit RGB class and 8,000 x 8,000
pixel resolution were extracted from each virtual slide with the NanoZoomer Toolkit (Hama-
matsu Photonics) and then converted to binary images with Image Pro-Plus 7.0 software
Photoacoustic Tomography for Breast Cancer Imaging
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(Media Cybernetics, Bethesda, MD, USA). The optimal hue, saturation and intensity (HSI) to
detect the maximum CD31 stained structures were selected for each virtual slide. A macro was
created for the automatic measurement of the perimeter of CD31-positive structures, regard-
less of shape, length or presence/absence of lumen, in all 105 jpegs. Each binary file was divided
into 16 squares of 0.84x0.84 mm. Total vessel perimeter (TVP) in each block of 0.84x0.84 mm
was calculated, and the data were automatically mapped for the whole histological slide using
the macro. After comparison with the HE slide, the blocks that corresponded to the lesion were
selected, and the whole lesional TVP was calculated. The ratio of lesional TVP (in μm) to
lesional area (in mm2) was used as a marker for each lesion. A representative case is shown in
Fig 1B and S2 Fig.
PAM assessments
The technical specification of the first version of the prototype machine used for this study has
been previously described in detail [13].In brief, a Ti:Sa laser optically pumped with a Q-
switched Nd:YAG laser is used, having a tunable wavelength in the range of 700 to 900 nm.
The measurable area was 30 mm by 46 mm for one scan, which took 45 seconds. Ultrasound
detector has a rectangular shape and consists of 345 elements, with 15 in the horizontal direc-
tion and 23 in the vertical direction. Each element size is 2mm and central frequency is 1 MHz.
For PAM imaging, the breast was placed between two holding plates craniocaudally with mini-
mum compression after applying acoustic coupling gel while the patient was in prone position
(Supplementary information, S1 Fig). Pulsed laser beams irradiated the breast from both sides,
and photoacoustic signals were detected on the caudal side by an array transducer. The array
number was 15 elements in the horizontal direction and 23 in the vertical direction. Each ele-
ment size was 2 mm squared. The measurable area was 30 mm x 46 mm for one scan, which
took 3 seconds for laser irradiation and 40 seconds for detector positioning. The array
Fig 1. Histological assessment of angiogenesis. (A) A representative histological section with HE, CD31 and CAIX staining (scale bar = 5 mm). Magnified
CD31-stained slide shows multiple microvessels (red arrowheads; 100x magnification; scale bar = 100 μm) (B)Map of total vessel perimeter of
CD31-positive structures in each block (0.84 x 0.84 mm). Lesional TVP (μm) to lesional area (mm2) ratio was calculated by selecting the blocks that
corresponded to the lesion area on the HE slide.
doi:10.1371/journal.pone.0139113.g001
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transducer could detect the signals up to the depth of 50 mm. In the first 16 cases, the scan was
performed at three adjacent areas where the lesion was considered to be located in the tumor-
bearing breast and one area in the normal contralateral breast. In later cases, the scanning sys-
tem automatically moved the array transducer in an area of 120 mm x 46 mm, which took 90
seconds for one automatic scan. The voxel pitch was set to 0.25 mm in each direction.
After data acquisition, photoacoustic image reconstruction was carried out using a modified
universal back projection algorithm [14]. Two-mmmaximum intensity projection (MIP)
images of PAM were constructed. Intensity, shape and continuity of the signals were the selec-
tion criteria for the classification of vessel- or microvessel-rich lesions. Linear, curling and
branching shaped signals were defined as vessels, while focally scattered or grouped signals
were attributed to microvessel-rich lesions. Each MIP stack was compared to the MRI images
(obtained during radiological diagnosis), and the subcutaneous vessels that were visible both in
the MRI and PAM were adjusted to locate the lesion [i.e., ROI] in the PAM image (Supplemen-
tary information S3 Fig). A breast radiologist (with more than 10 years of experience) deter-
mined whether PAM signals were associated with the lesion based on the morphology,
intensity and distribution of the signals. The same signal depth was used to assign ROIs on the
contralateral breast. Based on PAM technology, at the wavelengths of 756 and 797 nm, HbO2
and Hb are the main absorbents of the light, and optical fluence distribution in breast tissue is
estimated based on absorption and scattering coefficients in each wavelength. The oxygen satu-
ration of hemoglobin (SO2) of the lesions was calculated in assigned ROIs, as well as in the sub-
cutaneous vessels, in both breasts using the equations below:
maðl1Þ ¼ εHbOðl1Þ  CHbO þ εHbðl1Þ  CHb





(λ1, λ2: 756 nm, 797 nm, μa: absorption coefficient, CHbO, CHb: concentration of HbO2 and Hb,
εHbO, εHb: molar extinction coefficients of HbO2 and Hb, respectively). After each laser was
emitted to the breast tissue, the local absorption of the light was followed by local thermal exci-
tation and expansion, which resulted in pressure rise, and finally, acoustic waves. The μa value
for each laser was calculated from the following equation: P0 = ΓμaF, (P0: initial pressure rise;
Γ: Gruneisen parameter = 0.20 at body temperature; F: light fluence). Then, μa was used in the
abovementioned equations to calculate SO2.There was a 90-second time interval between the
two data acquisitions after each laser emission. The variance of P0, as well as F, can result in
the variance of μa, which may explain why the calculated SO2 was more than 100% in a few
cases.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for the Social Sciences) for Microsoft Win-
dows, version 20.0 (SPSS, Chicago, IL, USA). The nonparametric Mann-Whitney U-test was
used to compare variables between two groups, and the Kruskal-Wallis test was used when
there were more than two groups. The Wilcoxon signed-rank test was used to determine the
difference in SO2 between the lesional and subcutaneous vascular ROIs or between the lesional
and contralateral breasts. The Pearson's chi-square test of association was used to determine if
there was a relationship between two categorical variables. Pearson’s correlation analysis was
used to determine a significant relationship between lesional TVP/area and calculated SO2 for
continuous variables. Differences with a p value<5% were considered statistically significant.
Values are expressed as median (range) unless otherwise specified.
Photoacoustic Tomography for Breast Cancer Imaging
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Results
A total of 57 women were eligible for this study, and 40 participated in the study. Seventeen
cases were excluded from PAMmeasurement due to small breast size, anatomical location of
the lesion, physical difficulty of the patient laying in the prone position or patient withdrawal.
Two patients had masses in both breasts. In total, 42 mass-bearing breasts were scanned using
PAM. Three lesions were found to be benign after pathological exam and were excluded from
the statistical analysis. For 10 cases, no lesion-associated signal was detected after adjusting
with the MRI image. Twenty-nine breasts showed acceptable lesion-associated PAM signals.
Table 1 shows the basic patient characteristics in these two groups (i.e., lesion-associated signal
present vs. absent). There were no differences between the breast area and breast tissue thick-
ness of the tumor-bearing breasts in these two groups (S1 Table).
Signals from ROIs were detected at a median depth of 26.02 mm (3.25–51.2) in cases with
lesion-associated PAM signals. Thirty-three out of 39 lesions were confirmed to be IBCs.
Tumor size, lymph node status, histological grade, ER, PgR and HER-2 status, Ki67-index,
neoadjuvant treatment, CAIX expression and lesional TVP/area were not significantly different
between IBCs in the two PAM image groups (S2 Table).
The oxygen saturation level in all of the measured lesions was lower than that in the subcu-
taneous counterpart vessels (Wilcoxon test, p value<0.001, Fig 2A), as well as the counterpart
contralateral normal breast ROIs (Wilcoxon test, p value = 0.001, Fig 2B). Normal breast ROIs
showed the highest oxygen saturation level when compared with DCIS or IBC ROIs (S4 Fig).
Table 2 summarizes the histological angiogenic profile of all cases. While none of the DCIS
cases expressed CAIX, one third of IBCs in the study population expressed CAIX focally (11/
33), with a significantly higher lesional TVP/area (Mann-Whitney U-test, p value = 0.029).
While 42.9% of the cases that had not received PST expressed CAIX, only 15.3% of the cases
after PST were CAIX positive (S3 Table). The effect of PST on lesional TVP/area was consistent
with CAIX expression (S4 Table). We performed the analysis in the divided groups based on
PST history to test whether the histological angiogenic profile had any correlation with the
Table 1. Patient characteristics.
Lesion-associated PAM signal present (n = 29) Lesion-associated PAM signal absent (n = 10) P value




Body mass index 23.4 (17.7–31.6) 25.1 (17.8–27.3) 0.32
History of PST 0.44
Yes 9 4
No 20 6
Mass anatomical location 0.30
Superior to nipple 23 6





Lesional TVP/area 6.3 (2.4–15.9) 5.3 (2.1–18.4) 0.46
⌘Kruskal-Wallis test
doi:10.1371/journal.pone.0139113.t001
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calculated oxygen saturation. Although the oxygen saturation level was not significantly differ-
ent between CAIX positive vs. negative cases (Fig 3), lesional TVP/area showed a positive cor-
relation with oxygen saturation level only in the group that had received PST (Fig 4).
Discussion
Angiogenesis, a hallmark of all cancers [15], occurs in the very early stages of breast cancer
development [16]. In histological studies, periductal vascularity has been shown to be signifi-
cantly higher when compared between normal and hyperplastic ducts in breast tissue from
patients with DCIS [8,16]. Additionally, antiangiogenic therapies in which abnormal tumor
vasculature is targeted for normalization are among the emerging therapeutic approaches for
breast cancer [17]. Thus, imaging angiogenesis has been a topic of interest for the development
of new techniques for detecting breast cancer, as well as for a noninvasive monitoring tool dur-
ing treatment [18]. PAM is a new modality based on photoacoustic tomography [19] in which
Fig 2. Oxygen saturation level of analyzed ROIs. (A)Oxygen saturation level in 28 lesions and the subcutaneous counterpart vessels. (Wilcoxon test, p
value<0.001,❊❊❊). (B)Oxygen saturation level in 22 lesions and the counterpart contralateral normal breast ROIs (Wilcoxon test, p value = 0.001❊❊).
Box plots present the median and 1st and 3rd quartiles.
doi:10.1371/journal.pone.0139113.g002
Table 2. Correlation between histological angiogenic profile in malignant cases (n = 39).
DCIS (n = 6) Lesional TVP/area Invasive (n = 33) Lesional TVP/area
CAIX expression ⌘
Positive 0 11 8.1 (3.4–18.4)
Negative 6 5.46 (2.1–15.9) 22 4.44 (2.4–13)
⌘ Mann-Whitney U-test, P value = 0.029
doi:10.1371/journal.pone.0139113.t002
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the breast is emitted with light at a wavelength that is best absorbed by the chromophores, such
as Hb and HbO2, which play a role in the optical contrast between malignant and normal
breast tissue due to enhanced angiogenesis in cancerous lesions [20]. The absorbed light causes
thermoelastic expansion, resulting in a pressure increase that can be detected by ultrasound
detectors after propagation. High spatial resolution ultrasound in breast tissue enables the
lesions to be quantitatively analyzed by PAM, and high spatial resolution of PAM is superior to
other optical imaging modalities that use hemoglobin concentration differences between
malignant and normal mammary tissue as the imaging contrast [21]. Several groups have
designed and developed devices based on the photoacoustic technique and have tested the lab-
oratory prototype in clinical settings [22,23], but to the best of our knowledge, this is the first
clinical study to evaluate the clinical application of PAM to this extent.
In this initial clinical trial, the visual assessment of the breast and tumor vasculature,
through mapping of PAM signals, was possible in 29 out of 39 breasts (visibility rate 74.4%). In
the other 10 cases, detected signals did not show a specific pattern for classification as a micro-
vessel-rich lesion. Theoretically, this difficulty must have arisen from the presence of the same-
level signal from surrounding tissue in these cases. Technical reasons for this limitation could
also be due to the following variables: incorrect operator setting, insufficient amount of applied
gel or improper compression of the breast between the probe and detector. Breast size may also
interfere with proper compression and may result in a higher background signal level.
Fig 3. Oxygen saturation level in different CAIX expression groups.CAIX-negative group (n = 21):
68.67% (41.5%-92.05%); CAIX-positive group (n = 8); 72.61% (35.01%-83.36%). Mann-Whitney U-test, p
value = 0.77
doi:10.1371/journal.pone.0139113.g003
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However, this study was performed in an Asian population, and body mass index was in the
same range for both groups (Table 1). We also measured the breast area using the pictures
taken with the built-in camera (S3 Fig). Neither breast area nor breast thickness (measured
automatically after setting the breast between the holding plates) showed a difference between
cases with vs. without lesion-associated signals (S1 Table). Non-technical factors could also be
the result of an ill-structured breast vasculature. To detect mammary tissue-related factors, we
analyzed both patient and lesion characteristics in the two groups. Although it was found by
Doppler [24] that breast vessel variables are dependent on the menstrual status of cases studied,
neither age nor menstrual status in our study seemed to be of statistical significance when com-
pared between cases that were visible and non-visible by PAM.
Contrast-enhanced MRI studies that measure the number of total vessels longer than 3 cm
in length with a maximum transverse diameter greater than 2 mm have shown that ipsilateral
whole-breast vascularity asymmetrically increases in DCIS, as well as in IBC [25]. This finding
may represent an underlying reason for an increased background signal level.
Diffuse optical spectroscopy imaging (DOSI) is another modality in which the breast is
emitted with a wide range (600–1,100 nm) of light, and the optical signals are detected after
passing through the tissue [26]. When measured with DOSI, the hemoglobin distribution pat-
tern in tumor-bearing breasts was mapped as hot-spots or uniform based on the difference
between the lesions and normal tissue [27]. In a clinical study of 118 breast cancer patients,
37.3% of the breasts showed a uniform pattern, which could imply a global rise in hemoglobin
in these breasts [28]. These data are comparable to the 25.6% rate of non-visibility by PAM
Fig 4. Correlation between lesional TVP /area and calculated oxygen saturation level. Pearson’s correlation coefficient between lesional TVP /area and
calculated oxygen saturation level (A) in cases after PST (n = 9; R2 = 0.04234, p value = 0.053), and (B) in cases without PST (n = 20; R2 = 0.0392, p
value = 0.405).
doi:10.1371/journal.pone.0139113.g004
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found in our study; the visibility rate by PAM (74.4%) was within the acceptable range in our
study, given that the study population (initial 42 lesions) was a heterogeneous group of cases,
some of which had received PST. Of note, one of the three benign lesions that were excluded
from the statistical analysis was from a patient who showed a complete pathological response
(pCR) after PST. In addition, 4 out of 10 non-visible cases had undergone neoadjuvant thera-
pies, and the morphologic effects of PST on whole-breast stromal tissue may have been a factor
in these cases [29]. Two of the non-visible cases were reported to be mucinous carcinoma, and
colloid constituents of these tumors may have distorted the PAM signal [30]. However, the
IBC visibility rate remained the same (72.7%), and no clinicopathological factor seemed to be
of significant difference between the two groups. Only one out of six DCIS cases evaluated by
PAM was non-visible, and this patient had achieved a grade 3 pathological response to PST.
The calculated SO2 values in the subcutaneous vasculature, both on the tumor side and con-
tralateral breast side, were comparable (median 85.5% vs. 86.4%, respectively, data not shown).
This result implies that breast compression during PAM did not affect blood circulation or
oxygenation in the breast tissue. With this in mind, the lower lesional SO2 values in breast
lesions compared to normal ROIs suggest reduced tissue oxygenation and hypoxia in malig-
nant tumors. This result is in accordance with previously reported tissue oxygenation data
from DOSI studies [28,31].
For testing the possible correlation between clinically measured lesional SO2 by PAM and
histological angiogenic characteristics, we performed auto-image analysis on CD31-stained
histological sections from all cases. Using this method, we were able to measure the histological
quantitative characteristics of tumor microvessels (i.e., vessel count, vessel area, vessel perime-
ter) on the greatest dimension tumor section and the adjacent area, unlike manual measure-
ment where hot spots are randomly selected by investigators. Our preliminary data showed
that among the mentioned quantitative parameters, vascular perimeter was more coherent
than the manually measured parameters in the selected areas (data not shown). We also calcu-
lated TVP and normalized this value to the surface area of each lesion (lesional TVP/area).
Indeed, lesional TVP/area was shown to be correlated with CAIX expression, which is another
accepted marker for hypoxia in breast cancer (Table 2) [32]. Neoadjuvant treatments decrease
tumor cellularity, and in some cases, normalize the tumor microenvironment [33,34]. In 39
cases for which histological assessment was performed, the distribution pattern of lesional
TVP/area, as well as CAIX, was different based on PST history (S3 and S4 Tables). However, a
history of PST did not have an impact on the calculated lesional SO2 among the 29 cases (S5
Table).
A previous study demonstrated that the SO2 level was higher in 12 patients who achieved
pCR after neoadjuvant therapy in comparison to 30 non-pCR cases [35]. In our study, none of
the visible cases by PAM had achieved pCR, and due to the small sample size, we could not per-
form statistical analyses on the correlation between the grade of response to treatment and SO2
level. In this study, histological angiogenic parameters were not clearly related to calculated
lesional SO2 (Fig 3, Fig 4), which may be due to the study population background (e.g., different
PST regimens) or to nonhypoxic stimuli that influence CAIX expression [36]. In cases after
PST, the positive correlation between lesional TVP/area and SO2 may be the reason for an
increase in the number of functional microvessels; however, further studies on a more homoge-
nous population, as well as an assessment of other microvessel characteristics such as shape
[37] and maturity [38], are necessary to test this observation.
There were several potential limitations of this study. First, the breasts were mildly com-
pressed in the craniocaudal direction between the two plates for PAM imaging, which differs
from breast positioning in MRI, and we compared PAM signal with MRI images to locate the
tumor in PAM after adjusting the subcutaneous vessels in both images. Although this was the
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best method available at the time, tumor location using both methods may not always be pre-
cisely identical. Another limitation was the imaging resolution, which was approximately 2
mm. The next-generation PAMmachine should be designed with these limitations in mind.
In conclusion, vascular and oxygenation images obtained by PAM represent a new, non-
invasive imaging method with great potential for providing functional features of breast
tumors. Although technical improvements, such as higher resolution, are needed before testing
its application for breast cancer diagnosis, oxygenation mapping of the whole breast could
detect less-oxygenated areas in malignant cases. In the era of neoadjuvant therapies becoming
a significant part of routine clinical practice, non-invasive tumor angiogenesis imaging modali-
ties can provide helpful information for finding predictive, as well as prognostic, factors.
Supporting Information
S1 Fig. Schematic of the prototype machine used for this study.
(JPG)
S2 Fig. A representative case and histological assessment.
(JPG)
S3 Fig. Measurements of breast area and breast thickness.
(JPG)
S4 Fig. Oxygen saturation level in different groups ROIs.
(JPG)
S1 Table. Breast area and breast tissue thickness of tumor-bearing breasts in the study pop-
ulation.
(DOCX)
S2 Table. Histopathological characteristics of invasive carcinomas.
(DOCX)
S3 Table. CAIX expression in different PST groups.
(DOCX)
S4 Table. Lesional TVP/area in different PST groups.
(DOCX)
S5 Table. Lesional oxygen saturation level (SO2) in different PST groups.
(DOCX)
Acknowledgments
The authors thank the surgeons of the Department of Breast Surgery, Kyoto University, Drs.
Megumi Takeuchi, Takayuki Ueno, Wakako Tsuji, Eiji Suzuki and Yuko Mitsudo, and the clin-
ical research coordinator, Tomoko Kosaka, for their sincere cooperation.
Author Contributions
Conceived and designed the experiments: EF YA T. Sugie T. Shiina M. Toi. Performed the
experiments: EF M. Torii TK YH IY. Analyzed the data: EF M. Torii TK SK YMMK KTM.
Takada M. Toi. Contributed reagents/materials/analysis tools: YM HH. Wrote the paper: EF
M. Torii YA.
Photoacoustic Tomography for Breast Cancer Imaging
PLOS ONE | DOI:10.1371/journal.pone.0139113 October 27, 2015 11 / 13
References
1. Globocan 2012. Available: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al (eds). SEER Cancer
Statistics Review, 1975–2011, National Cancer Institute. Bethesda, MD. Available: http://seer.cancer.
gov/csr/1975_2011/. Based on November 2013 SEER data submission, posted to the SEER web site,
April 2014.
3. Lee CI,Elmore JG (2014). Breast cancer screening. In: Harris JR, Lippman ME, Morrow M, Osborne
CK editors. Disease of the breast. Wolters Kluwer Health. pp 90–95.
4. Ho JM, Jafferjee N, Covarrubias GM, Ghesani M, Handler B (2014) Dense breasts: a review of report-
ing legislation and available supplemental screening options. AJR Am J Roentgenol. 203:449–56. doi:
10.2214/AJR.13.11969 PMID: 25055284
5. Knuttel FM, Menezes GL, van den Bosch MA, Gilhuijs KG, Peters NH (2014) Current clinical indications
for magnetic resonance imaging of the breast. J Surg Oncol. 110:26–31. doi: 10.1002/jso.23655 PMID:
24861355
6. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol. 26:4012–21. doi: 10.
1200/JCO.2007.14.3065 PMID: 18711192
7. Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, et al. (2005) Imaging in breast can-
cer: diffuse optics in breast cancer: detecting tumors in pre-menopausal women and monitoring neoad-
juvant chemotherapy. Breast Cancer Res. 7:279–85 PMID: 16457705
8. Carpenter PM, ChenWP, Mendez A, McLaren CE, Su MY (2011) Angiogenesis in the progression of
breast ductal proliferations. Int J Surg Pathol. 19:335–41. doi: 10.1177/1066896909333511 PMID:
19403546
9. Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. (1999) Reduction in angiogenesis
after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer.
85:1996–2000. PMID: 10223241
10. Tynninen O, Sjöström J, von Boguslawski K, Bengtsson NO, Heikkilä R, Malmström P, et al. (2002)
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients. Br J
Cancer. 86:1905–8. PMID: 12085184
11. Manohar S, Kharine A, van Hespen JC, SteenbergenW, van Leeuwen TG (2005) The Twente Photoa-
coustic Mammoscope: system overview and performance. Phys Med Biol. 50:2543–57. PMID:
15901953
12. Yuan B, Rychak J (2013) Tumor functional and molecular imaging utilizing ultrasound and ultrasound-
mediated optical techniques. Am J Pathol. 182:305–11. doi: 10.1016/j.ajpath.2012.07.036 PMID:
23219728
13. Kitai T, Torii M, Sugie T, Kanao S, Mikami Y,Shiina T, et al. (2014) Photoacoustic mammography: initial
clinical results. Breast Cancer. 21:146–53. doi: 10.1007/s12282-012-0363-0 PMID: 22484692
14. Fukutani K, Someda Y, Taku M, Asao Y, Kobayashi S, Yagi T, et al. (2011) Characterization of photoa-
coustic tomography system with dual illumination. Proc SPIE . 7899:78992J
15. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation.Cell. 144:646–74. doi: 10.
1016/j.cell.2011.02.013 PMID: 21376230
16. Ottinetti A, Sapino A(1988) Morphometric evaluation of microvessels surrounding hyperplastic and
neoplastic mammary lesions. Breast Cancer Res Treat. 113:241–8.
17. Fakhrejahani E, Toi M (2014) Antiangiogenesis therapy for breast cancer: an update and perspectives
from clinical trials. Jpn J Clin Oncol. 44:197–207 doi: 10.1093/jjco/hyt201 PMID: 24474817
18. HeijblomM, Klaase JM, van den Engh FM, van Leeuwen TG, SteenbergenW, Manohar S.(2011) Imag-
ing tumor vascularization for detection and diagnosis of breast cancer. Technol Cancer Res Treat.
10:607–23. PMID: 22066601
19. Mehrmohammadi M, Yoon SJ, Yeager D, Emelianov SY (2013) Photoacoustic imaging for cancer
detection and staging. Curr Mol Imaging. 2:89–105. PMID: 24032095
20. Oraevsky AA (2009) Optoacoustic tomography of the breast. In: Wang LV editor. Photoacoustic imag-
ing and spectroscopy. CRC Press.pp 411–429.
21. Wang LV, Hu S (2012) Photoacoustic tomography: In vivo imaging from organelles to organs. Science.
335: 1458–1462. doi: 10.1126/science.1216210 PMID: 22442475
22. Kruger RA, Kuzmiak CM, Lam RB, Reinecke DR, Del Rio SP, Steed D.l (2013) Dedicated 3D photoa-
coustic breast imaging. Med Phys. 40:113301. doi: 10.1118/1.4824317 PMID: 24320471
23. Manohar S, Vaartjes SE, Hespen JCG, Klasse JM, Engh FM, SteenbergenW, et al (2007) Initial results
of in vivo non-invasive cancer imaging in the human breast using near-infrared photoacoustics. Opt
Exp. 15:12277–85.
Photoacoustic Tomography for Breast Cancer Imaging
PLOS ONE | DOI:10.1371/journal.pone.0139113 October 27, 2015 12 / 13
24. Germer U, Tetzlaff A, Geipel A, Diedrich K, Gembruch U (2002) Strong impact of estrogen environment
on Doppler variables used for differentiation between benign and malignant breast lesions. Ultrasound
Obstet Gynecol. 19:380–5. PMID: 11952968
25. Sardanelli F, Iozzelli A, Fausto A, Carriero A, Kirchin MA (2005) Gadobenate dimeglumine-enhanced
MR imaging breast vascular maps: association between invasive cancer and ipsilateral increased vas-
cularity. Radiology. 235:791–7. PMID: 15845796
26. Taroni P (2012) Diffuse optical imaging and spectroscopy of the breast: a brief outline of history and
perspectives. Photochem Photobiol Sci. 11:241–50. doi: 10.1039/c1pp05230f PMID: 22094324
27. Ueda S, Nakamiya N, Matsuura K, Shigekawa T, Sano H, Hirokawa E, et al. (2013) Optical imaging of
tumor vascularity associated with proliferation and glucose metabolism in early breast cancer: clinical
application of total hemoglobin measurements in the breast. BMCCancer. 13:514. doi: 10.1186/1471-
2407-13-514 PMID: 24176197
28. Nakamiya N, Ueda S, Shigekawa T, Takeuchi H, Sano H, Hirokawa E, et al.(2014) Clinicopathological
and prognostic impact of imaging of breast cancer angiogenesis and hypoxia using diffuse optical spec-
troscopy. Cancer Sci. 105:833–9. doi: 10.1111/cas.12432 PMID: 24766271
29. Martincich L, Bertotto I, Montemurro F, Ponzone R, Carbonaro LA, Regge D, et al.(2011) Variation of
breast vascular maps on dynamic contrast-enhanced MRI after primary chemotherapy of locally
advanced breast cancer. AJR Am J Roentgenol. 196:1214–8. doi: 10.2214/AJR.10.5239 PMID:
21512094
30. Corben AD, Brogi E (2014) Mucinous carcinoma. In: Hoda SA,Brogi E, Koerner FC, Rosen PP editors.
Rosen’s breast pathology. Wolters Kluwer Health.pp 611–44.
31. Flexman ML, Kim HK, Gunther JE, Lim EA, Alvarez MC, Desperito E, et al. (2013) Optical biomarkers
for breast cancer derived from dynamic diffuse optical tomography. J Biomed Opt. 18:096012. doi: 10.
1117/1.JBO.18.9.096012 PMID: 24048367
32. Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, et al. (2001) Prognostic significance of
a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol.
19:3660–8. PMID: 11504747
33. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L,et al. (2004) Change in tumor cellularity of
breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of
response. Cancer. 100:1365–73. PMID: 15042669
34. Jain RK.(2013) Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J
Clin Oncol. 31:2205–18 doi: 10.1200/JCO.2012.46.3653 PMID: 23669226
35. Ueda S, Roblyer D, Cerussi A, Durkin A, Leproux A, Santoro Y, et al. (2012) Baseline tumor oxygen sat-
uration correlates with a pathologic complete response in breast cancer patients undergoing neoadju-
vant chemotherapy. Cancer Res. 72:4318–28. doi: 10.1158/0008-5472.CAN-12-0056 PMID:
22777823
36. Vordermark D, Kaffer A, Riedl S, Katzer A, Flentje M.(2005) Characterization of carbonic anhydrase IX
(CAIX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol
Phys. 61:1197–207. PMID: 15752902
37. Fakhrejahani E, Asao Y, Toi M (2014) Tumor microvasculature characteristics studied by image analy-
sis: Histologically-driven angiogenic profile. Int J Biol Markers. 29:e204–7. doi: 10.5301/jbm.5000098
PMID: 25041785
38. Raza A, Franklin MJ, Dudek AZ (2010) Pericytes and vessel maturation during tumor angiogenesis and
metastasis. Am J Hematol. 85:593–8. doi: 10.1002/ajh.21745 PMID: 20540157
Photoacoustic Tomography for Breast Cancer Imaging
PLOS ONE | DOI:10.1371/journal.pone.0139113 October 27, 2015 13 / 13
